跳至主要内容
临床试验/CTRI/2018/05/014303
CTRI/2018/05/014303招募中不适用

A Non-Interventional, Multicenter, Prospective, Observational Study to Understand Usage and Effect of AZilsartan as MonothErapy or Add On TreatmeNt in Indian PaTients with Hypertension

Torrent Pharmaceuticals Ltd1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2018年9月5日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000
试验地点
1
主要终点
1.To assess the mean change in clinic SBP and DBP levels from baseline to week 12

研究概览

简要总结

This Non-Interventional, Multicenter, Prospective, Observational Study is to UNderstand the Effect of Azilsartan as monotherapy or add on treatment in Indian patients with hypertension (ZENITH Study). Total 1000 patients are planned from 20 different sites across India. The primary objective of the study is to assess the mean change in clinic SBP and DBP levels from baseline to week 12 in routine clinical practice treated with azilsartan either alone or add on therapy. Secondary objectives of study are (i) Percentage of participants with response [Time Frame: Baseline and week 12] (ii) Percentage of participants who achieve target BP <140 mm Hg (iii) To understand usage pattern of azilsartan as monotherapy or add-on with other antihypertensive drugs and  (iv) to assess adverse events during study duration

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 85.00 Year(s)(—)
性别
All

入选标准

  • 1.Patient willing to provide informed consent 2.Female or male patient aged 18 years or above 3.A treatment naive patient or a patient who are on treatment with other antihypertensive with grade 1 and 2 hypertension (SBP between 150 to 180) 4.Physician decides to prescribe azilsartan as a monotherapy or add-on 5.Patients must provide written consent to use personal and/or health data prior to the entry into the study.

排除标准

  • 1.Confirmed secondary hypertension 2.Patient taking a medicine acts upon RAAS e.g. ACEi or ARBs other than Azilsartan 3.Contraindications for azilsartan of respective approved local prescribing information.
  • 4.Any reasons of medical and non-medical character, which in the opinion of the physician can prevent subject participation in the study 5.Pregnant and lactating woman and women of child bearing potential not ready to use an effective barrier contraceptive method during the study.

结局指标

主要结局

1.To assess the mean change in clinic SBP and DBP levels from baseline to week 12

时间窗: At baseline | At end of 12weeks

次要结局

  • 1.Percentage of Participants With Response. Response is defined as decrease of SBP ≥20 mm Hg or decrease of DBP ≥10 mm Hg.(2. Percentage of Participants who Achieve Target BP 140 mm Hg.Target BP is defined as SBP 140 mm Hg and DBP 90 mm Hg.)

研究者

发起方
Torrent Pharmaceuticals Ltd
申办方类型
Pharmaceutical industry-Indian

研究点 (1)

Loading locations...

相似试验

An observational study to understand usage and... | 临床试验